2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
10
Radiotherapy
5
Carboplatin
5
Vincristine
4
Radiosurgery
4
Surveys and Questionnaires
3
Magnetic Resonance Imaging
3
Etoposide
3
Bevacizumab
3
etoposide phosphate
2
Vorinostat
2
Magnetic Resonance Spectroscopy
2
Lomustine
2
Irinotecan
2
Immunoglobulin G
2
Ifosfamide
2
Fluorodeoxyglucose F18
2
Disulfides
2
Cisplatin
2
veliparib
1
tozuleristide
1
romidepsin
1
perillyl alcohol
1
pembrolizumab
1
olutasidenib
1
lonafarnib
1
ispinesib
1
emvododstat
1
cediranib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinal Cord Neoplasms
×
RRx-001
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled